

ASX ANNOUNCEMENT / MEDIA RELEASE
ASX: (NXS)

Appointment of new Director

Sydney, Australia Tuesday, 24 October 2023, Next Science Limited (ASX:NXS) (**Next Science** or the **Company**) a medical technology company focused on commercialising its proprietary XBio™ suite of products to reduce the impact of biofilm-based infections in human health, announces the appointment of Ms Katherine Ostin as an independent Non-Executive Director of the Company and Chair of the Board's Audit and Risk Committee with effect from Tuesday, 24 October 2023.

Ms Ostin is an experienced non-executive director and audit and risk committee chair. Ms Ostin's appointment strengthens the Board's skills in a number of key areas including finance and accounting, audit, risk, governance, strategy and business development.

Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms Ostin worked in Australia, the US, Asia, and the UK.

Ms Ostin currently serves as a Non-Executive Director of 3P Learning Limited (ASX:3PL), dusk Group Limited (ASX:DSK), Capral Limited (ASX:CAA) and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms Ostin is also a graduate of the Australian Institute of Company Directors (AICD).

Commenting on Ms Ostin's appointment, Chair, Aileen Stockburger, said: "The Board is delighted to welcome Kathy. Kathy's experience will be of great value as the Company continues to grow and we look forward to her contributions."

Further Information:

Martyn Jacobs

Head of Investor Relations

Phone: +61 412 785 180

Email: mjacobs@nextscience.com

Approved and authorised for release by the Managing Director and CEO.

Next Science Investor Hub

Next Science welcomes direct engagement and encourages shareholders and interested parties to visit the Next Science Investor Hub which provides additional background information, videos and a forum for stakeholders to communicate with each other and with the Company. Stakeholders can access the Investor Hub through the following link: <https://investorhub.nextscience.com/announcements>



About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com